Latest Conference Articles

The 5-year analysis of the CheckMate 227 study shows long-term survival benefit for nivolumab plus ipilimumab versus chemotherapy in patients with metastatic non–small cell lung cancer.

Patients with platinum-sensitive ovarian cancer treated with maintenance rucaparib in the ATHENA-MONO trial showed a significant improvement in progression-free survival when compared with placebo in the first-line setting, regardless of HRD status.

In patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer that has progressed after mobocertinib treatment, remaining on mobocertinib may be warranted, according to news research.

Lurbinectedin in combination with pembrolizumab in the second-line shows promising safety and efficacy in relapsed small cell lung cancer

According to Grzegorz S. Nowakowski, MD, results from a subgroup analysis of the observational RE-MIND study may aid in contextualizing therapy options for treating patients with relapsed or refractory diffuse large B-cell lymphoma.

Enzalutamide showed continued overall survival benefit in patients with metastatic hormone-sensitive prostate cancer after over 5 years of follow-up.

Adding tiragolumab to atezolizumab plus carboplatin and etoposide did not meet its mark of improving survival in patients with extensive-stage small-cell lung cancer.

IfIosfamide treatment improved event-free survival compared with topotecan plus cyclophosphamide in patients with relapsed/refractory Ewing sarcoma, phase 2/3 study results show.

Zenocutuzumab produced durable responses in patients with previously treated advanced NRG1-positive cancers and had an extremely well-tolerated toxicity profile, according to data from the 2022 ASCO Annual Meeting.

Adjuvant pembrolizumab improved distant metastasis-free survival and longer follow up for recurrence-free survival in patients with resected stage IIB or stage IIC melanoma, according to data discussed at the 2022 ASCO Annual Meeting.

Data showing the safety and efficacy of selpercatinib for patients with solid tumors continues to impress clinicians at the 2022 ASCO Annual Meeting.

At the 2022 ASCO Annual meeting, trastuzumab dreuxtecan was found to be a superior standard of care therapy for patients with hER2-low, hormone-positive metastatic breast cancer.

At the 2022 ASCO Annual Meeting, the primary analysis of the phase 2 PILOT study showed the durability and feasibility of lisocabtagene maraleucel as second-line therapy in certain patients with large B-cell lymphoma.

In elderly frail patients with relapsed/refractory multiple myeloma, treatment with ixazomib plus daratumumab achieved favorable response rates.

Combination of alpelisib and fulvestrant shows clinical benefit in patients with hormone receptor–positive, HER2-negative advanced breast cancer regardless of gene mutation status, according to a retrospective biomarker analysis.

At the 2022 ASCO Annual Meeting findings from the phase, 3 DETERMINATION trial showed off the survival benefit when adding autologous stem cell transplant and lenalidomide maintenance after RVd treatment for patients with newly diagnosed multiple myeloma.

Based on a 2022 ASCO Annual Meeting presentation given by Cyrille Touzeau, MD, PhD, the IFM 2018-04 study confirms the efficacy and feasibility of the quadruplet induction regimen Dara-KRd in high-risk, transplant-eligible patients with multiple myeloma.

Decreased risk of disease progression or death on second-line therapy with the combination of lenvatinib and pembrolizumab vs sunitinib in the CLEAR clinical trial.

Encouraging efficacy signals in heavily pretreated patients with advanced solid tumor has been demonstrated in AURELIO-03 trial, and will be further evaluated in AURELIO-304.

According to Alexander E. Drilon, MD, larotrectinib, regardless of tumor type in adult and pediatric and adult cancers with an NTRK fusion, can demonstrate very robust responses and durable responses.

Improvement in overall survival shown in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab, according to results from the phase 3 PARADIGM trial.

Among patients with newly diagnosed, transplant-eligible myeloma treated in a phase 2 study, induction and consolidation with daratumumab plus the RVd regimen outperformed RVd alone in terms of minimal residual disease and progression-free survival.

Treatment with ribociclib and an alternate endocrine therapy after progression on a prior CDK4/6 inhibitor improved progression-free survival over placebo and endocrine therapy in patients with HR-positive, HER2-negative unresectable or metastatic breast cancer, according to results of the randomized phase 2 MAINTAIN trial.

According to Ian E. Krop, MD, PhD, patritumab deruxtecan is responsible for producing clinically meaningful and durable antitumor activity in patients with HER3-expressing metastatic breast cancer, warranting further research.

First-line treatment with palbociclib plus letrozole demonstrated survival improvement vs letrozole monotherapy in patients with ER-positive/HER2-negative advanced breast cancer.

Findings from an arm of the EPCORE NHL-2 trial, presented at the 2022 ASCO Annual meeting, showed promising antitumor activity in patients with relapsed or refractory follicular lymphoma on subcutaneous epcoritamab combined with rituximab and lenalidomide.

A safety follow-up analysis of the randomized phase 3 DESTINY-Breast03 study reinforced the risk-benefit profile of trastuzumab deruxtecan compared with trastuzumab emtansine in patients with HER2-positive unresectable or metastatic breast cancer

After 2-years in the phase 2 POLARIS-3 clinical trial, toripalimab demonstrated clinical activity in patients with urothelial carcinoma.

According to , results from a phase 1 study support that on-target magrolimab-mediated anemia is manageable in patients with high-risk myelodysplastic syndrome and acute myeloid leukemia.

BTX-1188 could prevent systemic inflammatory dose-limiting toxicities that are usually attributed to pure GSPT1 degradation due to its immunomodulatory properties from the IKZF1/3 degradation.